Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matt Zuga Insider Profile
4 Followers
Matt Zuga, Director at TELA Bio, holds 211.44K shares in Acumen Pharmaceuticals (Ticker: ABOS), holds 514.48K shares in TELA Bio (Ticker: TELA), holds ― shares in Aziyo Biologics (Ticker: ELUT).
Matt Zuga has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Matt Zuga holds in companies
Most Profitable Insider Trade
The most profitable trade made by Matt Zuga
Matt Zuga's Trading History
TELA Bio
Nov 13, 2019
Director
Uninformative Buy
145.37K
$1.55M
Acumen Pharmaceuticals
Jan 19, 2024
CFO & Chief Business Officer
Uninformative Sell
15.70K
$682.97K
Aziyo Biologics
―
Director, Ten Percent Owner
―
―
List of latest transactions for each holding click on a transaction to see Matt Zuga's performance on stock
You May Also Like
Matt Zuga insider profile FAQ
What is the percentage of profitable transactions made by Matt Zuga?
The percentage of profitable transactions made by Matt Zuga is ―.
What is the average return per transaction made by Matt Zuga?
The average return per transaction made by Matt Zuga is ―.
What stocks does Matt Zuga hold?
Matt Zuga holds: TELA, ABOS, ELUT stocks.
What was Matt Zuga’s latest transaction?
Matt Zuga latest transaction was an Uninformative Sell of $15.70K.
What was Matt Zuga's most profitable transaction?
Matt Zuga’s most profitable transaction was an Informative Buy of TELA stock on November 13, 2019. The return on the trade was 32.00%.
What is Matt Zuga's role in TELA Bio?
Matt Zuga's role in TELA Bio is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.